Overview
Matricelf is a preclinical-stage biotechnology company specializing in personalized regenerative medicine through autologous 3D tissue engineering. The company develops patient-specific engineered neural implants derived from induced pluripotent stem cells (iPSCs) and extracellular matrix to address severe neurological injuries, with its lead program targeting spinal cord injury—a condition affecting hundreds of thousands globally with no curative treatment. By leveraging proprietary nanotechnology-based tissue regeneration, Matricelf aims to deliver one-time curative therapies that restore function and independence in patients with devastating neurological conditions. The company's platform technology has demonstrated compelling safety and functional recovery in FDA-accepted animal models, positioning it toward first-in-human clinical trials. Matricelf's broader vision extends beyond spinal cord injury to stroke, traumatic brain injury, and cardiovascular and retinal diseases.